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Abstract 
 
Negative symptoms remain an unmet clinical need, and yet have been generally associated with poor 
outcome in patients with schizophrenia. The association of negative symptoms with clinical features at 
presentation and with outcomes at 1 year were examined in a sample of first-episode psychosis patients in 
London (UK). Clinical data were utilized from five London Early Intervention Services included in the 
MiData audit database. The sample comprised 484 first-episode psychosis patients with complete Positive 
and Negative Syndrome Scale data at baseline and 1-year follow-up. Multiple imputation (N = 50) was 
conducted to account for missing follow-up data. Baseline negative symptoms were associated with male 
gender (B = -1.63, p <. 05), younger age of onset (B = -.15, p <. 05), a higher level of impairment on the 
Global Assessment of Functioning (disability) scale at baseline (B = -.19, p <. 010), an absence of 
reported substance misuse prior to baseline assessment (B = -3.05, p <. 001), and unemployment at 
baseline (B = -.93, p <. 01). At 1-year follow-up, negative symptoms at presentation were associated with 
worse Global Assessment of Functioning symptom (B = -.28, p <.01) and disability (B = -.27, p <. 05) 
scales, and with hospital admission (OR= 1.06, p <.01). Negative symptoms at presentation to Early 
Intervention Services were associated with poorer outcomes one year later. Future research is required to 
better understand the aetiology and trajectories of negative symptoms in early psychosis and propose 
novel targeted early interventions. 
 Key words: early intervention; first-episode psychosis; negative symptoms; psychosis; 
schizophrenia 
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1. Introduction 
Negative symptoms (NS) remain an unmet therapeutic need for people suffering from psychosis 
(Chue and Lalonde, 2014; Kirkpatrick, 2014; Millan et al., 2014). In first-episode psychosis (FEP) studies 
NS at onset have been linked with poor social functioning after the first year of treatment and at 2 and 
even 7 years after first presentation to services (Ayesa-Arriola et al., 2013; Best et al., 2014; Milev et al., 
2005). In a 3-year longitudinal study of first-episode non-affective psychosis, Ayesa-Arriola and 
colleagues (Ayesa-Arriola et al., 2013) also demonstrated that NS independently predicted impaired 
functioning at 1-year follow-up. Moreover, Best and colleagues (Best et al., 2014) indicated NS as the 
best symptomatic predictor of functioning both cross-sectionally and longitudinally in a FEP sample, in 
keeping with other early psychosis (Cacciotti-Saija et al., 2016) and mixed chronicity (Hunter and Barry, 
2012; Rabinowitz et al., 2012) studies.  
Research has also linked NS with symptomatic outcomes and recovery after a FEP. Among other 
variables, NS were reported as predictors of a continuous illness course at 5-year follow-up (Bertelsen et 
al., 2008) and were associated with a lower likelihood of achieving recovery (Gee et al., 2016; Novick et 
al., 2009; Schubert et al., 2015). Concerning the prognostic value of NS at onset, several studies have 
found that NS severity was associated with the likelihood of not achieving a clinical remission during one 
or two years of treatment (Díaz et al., 2013; Gaebel et al., 2014; Levine and Leucht, 2013; Üçok et al., 
2011; Verma et al., 2012). Moreover, lower level of NS at baseline (Üçok et al., 2011) have been found to 
predict remission in other FEP studies. Marchesi and colleagues (Marchesi et al., 2015, 2014a) showed 
that NS at onset were linked to poor outcome in terms of remission at 16 years. Another FEP follow-up 
study using the Danish OPUS cohort indicated that lower severity of NS at baseline along with earlier age 
of diagnosis predicted better rates of recovery, defined  as the combination of symptomatic and functional 
remission, at the 2- and at the 10-year follow-up assessment (Austin et al., 2013; Petersen et al., 2008). 
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Previous findings therefore suggest that high levels of NS have a debilitating effect on the early 
course of psychosis, despite the discrepancy of findings due to methodological variations across studies 
(Albert et al., 2011). However, NS have only been recently explored more extensively in the early course 
of psychosis, with only a few studies investigating their relationship with outcomes and baseline 
characteristics in FEP samples that included both affective and non-affective psychotic disorders. 
Moreover, there has been limited research investigating the impact of NS on outcomes of FEP patients 
being cared for by specialist services. Early Intervention Services (EIS) have been established across UK 
aiming to intervene early and effectively in young people experiencing FEP, following an assertive 
multidisciplinary outreach model, including pharmacological and psychosocial interventions (Fisher et 
al., 2008; Singh, 2010). Data utilized for the purposes of this naturalistic 1-year follow-up study were 
taken from five EIS in London, UK (Fisher et al., 2008). 
Therefore, the aims of this study were to examine: (1) possible baseline socio-demographic and 
clinical correlates of NS at first presentation to EIS, and (2) the relationship between NS at baseline with 
clinical and functional outcomes at 1-year follow-up. 
2. Material and Methods 
2.1 Setting 
This study was a naturalistic cohort of consecutive referrals to seven London EIS in the UK, assessed 
within one month of entry and followed up after one year. The teams were based in the following 
National Health Service (NHS) Mental Health Trusts in England: Camden and Islington (C&I EIS); 
South London and Maudsley (Lewisham EIS & STEP); East London and the City (EQUIP); Central and 
North West London (Brent and Kensington, Chelsea & Westminster EIS) and South West London and St. 
George’s (ETHOS).  
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2.2 Participants 
The patient inclusion criteria for EIS services were: (i) aged between 14 and 35 years old, (ii) 
presenting to the EIS for the first time with a psychotic episode lasting at least 7 days, and (iii) resident 
within the EIS catchment area (Fisher et al., 2008).  Patients with psychotic symptoms as a result of acute 
drug intoxication were excluded. 
2.3 MiData audit tool 
Data were collected using the MiData audit tool, a standardized computerised assessment package of 
a minimum set of assessments used in routine clinical practice in EIS. This tool was developed by the 
London Early Intervention Research Network in 2004 in order to ensure consistent auditing of the EIS 
across London (see the original MiData paper for more details) (Fisher et al., 2008). Baseline measures 
were completed by clinicians based on their routine comprehensive assessments within 1 month of entry 
to the EIS and then 1 year later (follow-up). All clinicians were trained and were expected to reach at least 
85% concordance with expert raters and other team members before being allowed to complete the 
measures on their patients (Kay et al., 1987).  
2.4 Assessment measures 
2.4.1 Socio-demographic information. Basic demographic data were obtained at baseline, 
including gender, age at onset of psychosis, employment status, and ethnicity based on the 2001 UK 
national census categories. Participants were assessed for the presence or absence of: (i) social support, 
with a categorization of ‘good’ (supportive and well-organized social environment, which benefits the 
patients’ recovery), ‘limited’ (existence of some level of social support, which does not cover all the 
needs of the patient) or ‘none’ (non-existent social networks); and (ii) family history of psychosis in a 
first-degree relative.  
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2.4.2. Clinical measures. At baseline, duration of untreated psychosis (DUP) was assessed with a 
revised version of the Nottingham Onset Schedule (Singh et al., 2005). DUP was defined as: the number 
of days between the appearance of the first positive psychotic symptom (hallucination, delusion or 
thought disorder) and the date that antipsychotic medication was initiated and thereafter taken for at least 
75% of the subsequent month. Individuals were assessed on the following measures at entry to the service 
and after 1 year in contact with the service: the Positive and Negative Syndrome Scale (PANSS)28 
including positive (PANSS-P), negative (PANSS-N) and general (PANSS-G) subscales; the Global 
Assessment of Functioning Scale for symptoms (GAF-s) and disability (GAF-d) (Endicott et al., 1976); 
and the Combined Alcohol and Drug Use Scale (Drake and Wallach, 1989; Fisher et al., 2008). 
International Classification of Diseases 10th edition (ICD-10) (World Health Organization, 1993) 
diagnosis was recorded at 1-year follow-up and was extracted from clinical records and confirmed with 
EIS consultant psychiatrists. These were grouped into schizophrenia-spectrum disorders (ICD-10 codes 
F20-29), affective psychoses (F30.2, F31.2, F31.5, F32.3, F33.3 or F39), and other disorders (all other 
codes).  
During the 1-year follow-up period, the occurrence of psychiatric admission to an in-patient 
ward, the use of a crisis or Home Treatment team (HTT), and the occurrence of any suicide attempts or of 
any violent incidents was determined from the clinical records. Adherence to treatment was ascertained 
using the treatment adherence subscale of the Service Engagement Scale (Tait et al., 2002), scored on a 
four-point Likert-type scale, with higher scores reflecting patients’ greater levels of non-compliance. 
Two new composite variables were created. Firstly, PANSS–D yielded presence of depression at 
baseline when patients had a score greater than 3 for all the following PANSS-G items: somatic concerns 
(G1), anxiety (G2), guilty feelings (G3) and depression (G6).(Kay and Sevy, 1990; Kjelby et al., 2011) 
This measure was created to ensure that the NS explored were not secondary to depression. Secondly, 
based on follow-up PANSS data, overall symptomatic Remission was defined as scores ≤3 on all of the 
following PANSS items: delusions (P1), unusual thought content (G9), hallucinations (P3), conceptual 
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disorganization (P2), mannerisms and posturing (G5), blunted affect (N1), social withdrawal (N4), and 
lack of spontaneity (N6). Overall symptomatic Remission was also calculated at baseline, using PANSS 
baseline data. Positive Symptom Remission was defined as scores ≤3 for the P1, P2, and P3 items at 1-
year follow-up (Andreasen et al., 2005). 
2.5 Preliminary data analysis 
The MiData data freeze used was dated 11th of August 2014, and consisted of 1108 patients. For the 
purpose of this study, only patients with fully completed PANSS data at baseline were included in the 
sample (N = 516). In order to explore any possible systematic bias, baseline clinical and 
sociodemographic variables in patients with fully completed baseline PANSS data were compared to 
patients with missing PANSS data using chi-square and independent samples t-tests as appropriate (see 
Supplementary Material Appendix A). Patients with fully completed PANSS data at baseline (N = 516, M 
(SD) = (7.64) 17.80) had lower scores on PANSS-P than those with missing data (N = 592, M (SD) = 
(7.74) 20.66, t (593) = 3.10, p <.01). Moreover, there was a significant difference between availability of 
PANSS total scores in different ethnic groups (χ2 (7) = 26.69, p < .001). In post-hoc chi-square analysis, 
compared to all other ethnicities, those of Asian ethnicity were more likely to have complete PANSS data 
and those with ethnicity recorded as “Black Other” were less likely to have complete PANSS data. No 
statistically significant differences were found regarding other variables (all p’s >.05). 
Normality and outliers testing was carried out for all continuous variables used in the analysis. 
Although Total Positive PANSS (PANSS-P), the Total Negative PANSS (PANSS-N) and the PANSS 
total were positively skewed, they were not transformed due to the large size of the sample and in order 
not to lose their clinical meaning. For the regressions, collinearity between independent variables was 
tested for with the variance inflation factor (VIF) (Field, 2009). 
2.6 Missing data and multiple imputation 
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Based on Missing Values Analysis (see Supplementary Material Appendix B), none of the patients 
from Lewisham and STEP EIS that were initially in the dataset had completed PANSS at 1-year follow-
up and consequently were excluded from the analysis. The remaining sample comprised 484 participants. 
Table 1 shows the rates of missing data for the variables used in this study. Little's missing completely at 
random (MCAR) test (Little and Rubin, 1991) for all the socio-demographic and clinical variables that 
were used for the main analyses of the study was not significant, suggesting that data were missing 
completely at random (χ2 (1069) = 904.11, p = 1.00). 
Missing values were imputed using Multiple Imputation (MI) creating 50 imputed data sets, with the 
SPSS Automatic method (see Supplementary Material Appendix C). Instead of using the totals for the 
PANSS subscales, all individual items were entered to enable creation of the composite variables of 
Remission and the PANSS-D factor. The number of imputations was similar to the highest percentage of 
missing cases.(White et al., 2011) The main analyses were conducted on the imputed datasets and the 
results were extracted from the pooled estimates.  
2.7 Main analyses 
Hierarchical linear regression was conducted in order to explore associations with socio-
demographic or key baseline clinical variables and baseline NS, with PANSS-N being the dependent 
variable. To investigate the relationship of baseline PANSS-N with outcomes at 1-year, multiple linear 
regressions and binomial logistic regressions were carried out for continuous and categorical outcome 
variables respectively, using baseline PANSS-N as the predictor in each case. The outcome variables at 1-
year follow-up were Remission, Positive Symptom Remission, GAF symptoms (GAF-s) and GAF 
disability (GAF-d), whether patients used Crisis teams, whether they were admitted to a psychiatric ward, 
whether they attempted suicide or whether they engaged in any violent incidents towards others. 
An adjusted estimate for each of the regressions was then calculated to take into account previous 
reports of clinical and demographic associations with outcome by including ethnicity (van der Ven et al., 
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2012; Veling, 2013),  social support at baseline (Norman et al., 2012, 2005), family history of psychosis 
(Esterberg and Compton, 2012),  gender (Galderisi et al., 2013; Tseliou et al., 2015), age at onset (Chang 
et al., 2012a; Malla, 2005), employment status at baseline (Abdel-Baki et al., 2013; Tandberg et al., 
2012), DUP (Chang et al., 2012b; Fraguas et al., 2014; Jeppesen et al., 2008; Tang et al., 2014), clinical 
diagnosis at 1-year follow-up (Lyne et al., 2012; Singh, 2000), adherence to medication (Alvarez-Jimenez 
et al., 2012) and substance abuse or dependence 6 months prior to assessment (Tarricone et al., 2014) as 
covariates. In addition, PANSS-D, PANSS-P and Remission status at baseline were included as 
covariates in order to control for depression and severity of psychotic symptoms at baseline. Lastly, since 
the data were drawn from different EIS in different parts of London, team was also included as a 
covariate in the adjusted model. All analyses were carried out using SPSS version 22 (IBM). 
2.8 Ethical Approval 
Data collection by each EIS was conducted in accordance with local audit procedures, which do not 
require patient consent. Any information that could lead to patient identification was removed (Fisher et 
al., 2008). Multi-centre ethical approval was obtained from the Wandsworth Research Ethics Committee, 
which granted permission for secondary research use of the data for a specific set of research questions, 
including NS and clinical outcomes.  
3. Results  
3.1 Sample characteristics at baseline assessment  
Socio-demographic and clinical characteristics of the sample (N = 484) are summarised in Table 2. 
Both pooled estimates from the 50 imputed datasets and the original dataset are presented. This sample 
comprised 315 males (61.5%) and the mean age of psychosis onset was 22.9 years (SD = 5.12).  
3.2 Baseline Negative Symptoms and characteristics at presentation to EIS 
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An exploratory forced entry hierarchical linear regression analysis revealed a significant association 
between baseline PANSS-N score and gender, age of onset, substance use in the preceding 6 months, 
occupation status and GAF-d score (R2 =.31, F (21, 462) = 12.75, p < .001; Table 3). Female participants 
had lower PANSS-N scores at baseline than males (p = .020); those with any substance use in the past 6 
months before baseline assessment had lower PANSS-N than those that had not used (p <.001); 
participants that were employed or in education at baseline scored lower on PANSS-N than those who 
were unemployed (p = .014); those with more impaired functioning had higher NS (p < .001); and 
younger age of onset was also associated with higher PANSS-N scores (p = .035).  
Post-hoc analysis of the relationship between PANSS-N at baseline and individual substance use 
including opioid, cannabinoid, alcohol, nicotine, cocaine and stimulant use in the model, revealed that 
only cannabinoid abuse or dependence was associated with lower PANSS-N scores (B = -2.17, B SE = 
.94, t = -2.39, 95% CI -4.01 – -.33, p =.021; Supplementary Materials, Table D1).  
3.3 Baseline NS and clinical outcomes at 1-year follow-up 
PANSS-N at baseline was significantly associated with worse symptoms (GAF-s; B = -.28, p =.007) 
and more impaired functioning (GAF-d; B = -.21, p = .01) at 1-year follow-up (Table 4). PANSS-N at 
baseline was also associated with patients being more likely to have been admitted to a psychiatric ward 
during 1-year follow-up, with one point increase in PANSS-N increasing the odds of being admitted 
during 1-year follow-up by 6%, (OR = 1.06, 95% CI 1.03 – 1.10, Wald statistic = 14.77, p =.001; Table 
5). The mean (SD) PANSS-N of those who were admitted (N = 206) was 18.70 (9.47) compared to 14.99 
(7.34) for those who were not admitted (N = 278). However, no significant associations were found 
between NS at baseline and Remission of symptoms at 1-year follow-up, nor with risk behaviors or use of 
HTT or Crisis teams during this period. 
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4. Discussion  
4.1 Negative symptoms: baseline correlates 
Participants with higher levels of baseline NS were much more likely to be male, in accordance with 
previous literature in both cross-sectional (Drake et al., 2016; Thorup et al., 2007) and follow-up FEP 
studies (Stone et al., 2014; Thorup et al., 2014). Thus, although earlier investigations of gender-specific 
patterns of negative psychopathology have been contradictory (Ochoa et al., 2012), most early psychosis 
studies are consistent with our findings (Köhler et al., 2009; Køster et al., 2008; Thorup et al., 2014, 2007; 
Willhite et al., 2008),  including at-risk for psychosis research (Rietschel et al., 2015). A recent 1-year 
follow-through study by Gee and colleagues (Gee et al., 2016) reported that stable high NS during the 
first year of treatment were also predicted by male gender.  
In the present study, severity of  baseline NS was also related to a younger age of psychosis onset, 
which is consistent with most (Ballageer et al., 2005; Dominguez et al., 2010; Drake et al., 2016; Üçok 
and Ergül, 2014), but not all (Schultz et al., 1997), previous findings. It is noteworthy that a recent meta-
analysis indicated that prominent NS at presentation for those under the age of 18 years of age should be 
considered as one of the core predictors for severe functional and clinical outcomes (Díaz-Caneja et al., 
2015). 
The present study suggests that patients with a higher level of NS had worse social and vocational 
functioning at baseline. This is in keeping with previous work in FEP patients by Best et al.(Best et al., 
2014) who found that NS were related to functioning, both cross-sectionally and longitudinally. Previous 
research with mixed samples in terms of illness chronicity, have also supported NS as the most 
functionally impairing symptom in psychosis, predicting both baseline functioning and change in 
12 
 
functioning with illness progression (Ayesa-Arriola et al., 2013; Hunter and Barry, 2012; Rabinowitz et 
al., 2012). Poor premorbid functioning in those with prominent levels of NS at first presentation with 
psychosis could explain the poor social functioning found at baseline (Chang et al., 2016). Thus, patients 
with NS might have already suffered functional deterioration during the at-risk phase of psychosis 
(Corcoran et al., 2011; Kim et al., 2013; Meyer et al., 2014), since NS seem to have a more insidious 
onset and to emerge before positive symptoms, with the latter usually leading to contact with EIS (Hafner 
et al., 1993; Harvey et al., 2006). 
We found that substance abuse or dependence in the 6-month period preceding entry to EIS was 
associated with lower levels of NS at presentation. Although there is a lack of FEP research on this 
relationship, existing studies are conflicting, with some being in agreement with the present result 
(Addington and Addington, 1998) and others not finding any differences in NS symptoms between 
substance users and non-users (Sevy et al., 2008). 
 In a post-hoc regression, only abuse of cannabinoids was a significant predictor for lower 
baseline NS levels, while accounting for other recent substance abuse (opioids, alcohol, nicotine, 
stimulants, cocaine). Again, although more research has investigated NS and cannabis use, there is no 
consensus with regards to their link. A few cross-sectional naturalistic FEP studies failed to find an 
association between cannabis use and NS (Carr et al., 2009; Hadden et al., 2016; Mané et al., 2015) 
whereas others have indicated that use within the 6 months prior to hospitalization was related to lower 
NS during admission for FEP patients (Compton et al., 2007). Additionally, a study with an at-risk for 
psychosis sample showed that increased consumption of cannabis was associated with fewer NS, before a 
full-blown psychotic episode (Seddon et al., 2016). 
Previous research has suggested that those experiencing a FEP may use cannabis to self-medicate 
(Khantzian, 1997), possibly alleviating some NS such as anhedonia (Gregg et al., 2007; Potvin et al., 
2005; Simon et al., 2015), or that higher NS could imply less hedonic capacity which in turn could reduce 
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drug-seeking (Compton et al., 2007). Another possible explanation is that those with less severe NS use 
more cannabis due to better functioning, i.e. are more capable of obtaining substances or more prone to 
substance abuse, as it has been indicated that FEP patients with cannabis abuse disorder show a stronger 
premorbid social functioning (Carr et al., 2009; Potvin et al., 2005). Nevertheless, there is still paucity of 
research, especially in FEP and more research is needed to clarify this association (Seddon et al., 2016; 
Simon et al., 2015). 
4.2 Negative symptoms: clinical and functional outcomes 
Baseline NS were related to higher possibility of admission to a psychiatric ward, used as a proxy of 
deterioration or relapse (Addington et al., 2013). Previous studies are in keeping with our findings 
indicating that high levels of baseline NS are related to poorer clinical outcome (Lang et al., 2013). 
Furthermore, previous studies generally support our finding that NS were significantly associated with 
admission one year after FEP (Morgan et al., 2006; Patel et al., 2015; Sipos, 2001), also reporting an 
associated increased duration of admission (Patel et al., 2015), and earlier relapse (Uçok et al., 2006), 
although one study did not replicate this finding (Addington et al., 2010). 
In this study baseline NS were associated by worse symptoms, as reflected in GAF-s and did not 
predict symptomatic remission at follow-up, being in accordance with previous 2- (Cesková et al., 2007) 
and 3-year follow-up FEP studies (Chang et al., 2012a). However, in other studies lower level of NS at 
baseline have been found to predict remission in first-episode patients after one or two years of treatment 
(Díaz et al., 2013; Gaebel et al., 2014; Levine and Leucht, 2013; Üçok et al., 2011; Verma et al., 2012) or 
even 16 years after FEP (Marchesi et al., 2014b, 2015). A possible explanation for the inconsistent 
findings is that it could mainly be persistent NS that predict follow-up non-remission (Chang et al., 
2012a; Edwards et al., 1999; Galderisi et al., 2013; Malla et al., 2004) and prevent patients from reaching 
a lasting remission state (Gaebel et al., 2014). Possible reasons for that would be their severely impairing 
and treatment-resistant nature (Üçok and Ergül, 2014), in addition to treatment discontinuation being 
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more prominent in patients with persistent NS (Galderisi et al., 2013).  In this study persistence of NS was 
not measured, thus we cannot contribute to this hypothesis.  
Risk behaviours, i.e. suicidality and violence incidents, were not predicted by NS levels. Our 
results are consistent with another FEP study that failed to find an association between NS and suicide 
attempts (Bertelsen et al., 2007). In a recent FEP study, the risk of suicide has been related to an increase 
in both positive and negative symptoms, thus with an overall escalating symptom severity (Mitter et al., 
2013). In a review, Pompili et al. (Pompili et al., 2011) indicated that more severe NS could predict 
suicidality in FEP via a possible increase in insight, which together with persistent reduced functioning 
and quality of life could increase hopelessness. However, others have suggested that prominent NS and 
especially expressive deficits could reduce the experience of distress caused by psychosis and thus the 
feeling of hopelessness is reduced, leading to decreased suicidal behavior (Chang et al., 2014). However, 
findings on the association between NS and suicidality remains inconsistent (Ventriglio et al., 2016). 
Violent incidents at follow-up and NS were not associated, being in agreement with FEP studies 
that have linked mainly positive (Foley et al., 2007; Winsper et al., 2013) or manic symptoms (Dean et 
al., 2007; Large and Nielssen, 2011) or no specific symptoms at all (Langeveld et al., 2014)  to violent 
behavior during FEP. Moreover, a recent study has indicated that there are diverse pathways to violent 
behavior following FEP, influenced by different profiles of premorbid delinquency, that should be taken 
into account in studies predicting violence in FEP (Winsper et al., 2013). 
Higher NS at baseline were also associated with worse functioning at 1-year follow-up as 
reflected by the GAF-d scores. This finding is consistent with most FEP studies to date that show NS as a 
critical determinant of both global and social functioning (Cacciotti-Saija et al., 2016) as well as real-
world functioning (Robertson et al., 2014), for at least 2 years after the FEP (Bergé et al., 2016).  Recent 
research has supported this link at the at-risk for psychosis stage as well (Meyer et al., 2014). Thus, it 
could be that those with high negative symptoms at presentation, even when these symptoms decrease, 
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are less likely to achieve recovery, which could be explained by highly disrupted premorbid functioning 
(Gee et al., 2016). 
4.3 Strengths and limitations 
This study has several strengths. The FEP sample was large, naturalistic, from different EIS within 
well-defined catchment areas, with minimal confounding effects of chronicity, institutionalization and 
prolonged exposure to antipsychotic treatment. Previous studies have indicated that FEP patients with 
higher NS might be at greater risk of dropping out (AlAqeel and Margolese, 2012; Thompson et al., 2011; 
Üçok and Ergül, 2014). Thus, although there was a considerable amount of missing data due to the 
naturalistic follow-up study design, MI was applied in order to correct for biases due to non-completion 
(Schafer and Graham, 2002). The differences between the original dataset and the pooled estimates 
showed that MI took into account the fact that those with missing follow-up data might have had high NS 
scores.  
Nonetheless, a number of caveats need to be considered. Firstly, due to the design of this study, some 
ethnic minorities and clinical subgroups might have been over/under-represented. Patients of Asian 
ethnicity were more likely to have completed the PANSS scale at baseline whereas those who identified 
themselves as “Black Other” ethnicity (i.e. not Black African, Caribbean or British) were less likely to 
have done so. This limits the generalizability of the findings. Concerning clinical characteristics, patients 
with lower severity of positive symptoms were more likely to have a fully completed PANSS at baseline, 
leading to over-representation of cases with lower positive symptoms. However, their mean difference 
was less than 3 points, possibly not representing a clinically significant difference. Additionally, cross-
sectional remission rate estimation at baseline and follow-up tends to be more vulnerable to confounding 
variables and lacks specificity. Thus, it has been suggested that in longitudinal investigations remission 
should be examined at six-month intervals (AlAqeel and Margolese, 2012; Gaebel et al., 2014), which 
was not possible in the current study. Lastly, regarding controlling for secondary NS, although this study 
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controlled for positive symptoms and depression, it did not take into account extra-pyramidal side-effects 
(EPS) since there was no measure available (Millan et al., 2014). 
6. Clinical implications 
The present findings suggest that NS are associated poorer global functioning and symptomatic 
outcomes and increased likelihood of admission, leading to several clinical implications. This is 
noteworthy since social and occupational functioning have been indicated as the most important recovery 
markers by both field experts (Kane et al., 2003) and experts by lived experience (Pitt et al., 2007).  Based 
on the relative fluctuation of NS in FEP and their increasing stability after the first year (Chang et al., 
2011; Ventura et al., 2015), this period might be a therapeutic window to ameliorate negative 
symptomatology, prevent disability and maximize functional outcome. Further investigations should 
examine the prognostic significance of timely, intensive and integrated intervention in NS during this 
potential critical period in preventing emergence of persistence. Careful monitoring of those showing 
higher NS at presentation warrants the attention of EIS,(Gee et al., 2016) if possible from the at-risk stage 
of the illness when NS often occur (Fusar-Poli et al., 2013). While emphasizing the need for specific 
treatment approaches for reducing the burden of NS (Schennach-Wolff et al., 2011; Verdoux et al., 2001), 
it might be important to distinguish between primary NS and secondary NS, as the latter can be subject to 
treatment changes (Carbon and Correll, 2014). 
7. Conclusion 
Negative symptoms in FEP are a significant problem, leading to worse functional and clinical 
outcomes even amongst patients treated by specialist services. Since pharmacological treatments (Fusar-
Poli et al., 2015) and psychosocial interventions (Jauhar et al., 2014; Østergaard Christensen et al., 2014) 
have shown to have little or no effect, further studies are needed in order to tackle NS, early and 
effectively, maximizing the long-term recovery for FEP patients.  
 
17 
 
Acknowledgements 
Initial pilot work within Camden and Islington EIS was supported by Islington Primary Care Trust. We 
are extremely grateful to clinicians and patients from the Early Intervention teams participating as part of 
the MiData Consortium for their time and enthusiasm. We would also like to thank Alexandros Rammos, 
PhD student at Trinity College, University of Dublin, who assisted on the supervision of statistical 
analyses for the first draft. This work was supported by the NIHR Biomedical Research Centre for Mental 
Health at the South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, King’s 
College London. 
 
  
 
 
 
 
 
 
 
 
 
 
18 
 
References  
Abdel-Baki, A., Létourneau, G., Morin, C., Ng, A., 2013. Resumption of work or studies after first-
episode psychosis: the impact of vocational case management. Early Interv Psychiatry 7, 391–
398. doi:10.1111/eip.12021 
Addington, D.E., Beck, C., Wang, J., Adams, B., Pryce, C., Zhu, H., Kang, J., McKenzie, E., 2010. 
Predictors of admission in first-episode psychosis: developing a risk adjustment model for service 
comparisons. Psychiatr Serv 61, 483–488. doi:10.1176/appi.ps.61.5.483 
Addington, D.E., Patten, S.B., McKenzie, E., Addington, J., 2013. Relationship Between Relapse and 
Hospitalization in First-Episode Psychosis. Psychiatric Services 64, 796–799. 
doi:10.1176/appi.ps.201200440 
Addington, J., Addington, D., 1998. Effect of substance misuse in early psychosis. Br J Psychiatry Suppl 
172, 134–136. 
AlAqeel, B., Margolese, H.C., 2012. Remission in schizophrenia: critical and systematic review. Harv 
Rev Psychiatry 20, 281–297. doi:10.3109/10673229.2012.747804 
Albert, N., Bertelsen, M., Thorup, A., Petersen, L., Jeppesen, P., Le Quack, P., Krarup, G., Jørgensen, P., 
Nordentoft, M., 2011. Predictors of recovery from psychosis. Schizophrenia Research 125, 257–
266. doi:10.1016/j.schres.2010.10.013 
Alvarez-Jimenez, M., Priede, A., Hetrick, S.E., Bendall, S., Killackey, E., Parker, A.G., McGorry, P.D., 
Gleeson, J.F., 2012. Risk factors for relapse following treatment for first episode psychosis: A 
systematic review and meta-analysis of longitudinal studies. Schizophrenia Research 139, 116–
128. doi:10.1016/j.schres.2012.05.007 
Andreasen, N.C., Carpenter, W.T., Kane, J.M., Lasser, R.A., Marder, S.R., Weinberger, D.R., 2005. 
Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162, 
441–449. doi:10.1176/appi.ajp.162.3.441 
Austin, S.F., Mors, O., Secher, R.G., Hjorthøj, C.R., Albert, N., Bertelsen, M., Jensen, H., Jeppesen, P., 
Petersen, L., Randers, L., Thorup, A., Nordentoft, M., 2013. Predictors of recovery in first 
episode psychosis: The OPUS cohort at 10year follow-up. Schizophrenia Research 150, 163–168. 
doi:10.1016/j.schres.2013.07.031 
Ayesa-Arriola, R., Manuel Rodríguez-Sánchez, J., Pérez-Iglesias, R., González-Blanch, C., Pardo-García, 
G., Tabares-Seisdedos, R., Vázquez-Barquero, J.L., Crespo-Facorro, B., 2013. The relevance of 
cognitive, clinical and premorbid variables in predicting functional outcome for individuals with 
first-episode psychosis: A 3 year longitudinal study. Psychiatry Research 209, 302–308. 
doi:10.1016/j.psychres.2013.01.024 
Ballageer, T., Malla, A., Manchanda, R., Takhar, J., Haricharan, R., 2005. Is adolescent-onset first-
episode psychosis different from adult onset? J Am Acad Child Adolesc Psychiatry 44, 782–789. 
doi:10.1097/01.chi.0000164591.55942.ea 
Bergé, D., Mané, A., Salgado, P., Cortizo, R., Garnier, C., Gomez, L., Diez-Aja, C., Bulbena, A., Pérez, 
V., 2016. Predictors of Relapse and Functioning in First-Episode Psychosis: A Two-Year Follow-
Up Study. Psychiatric Services 67, 227–233. doi:10.1176/appi.ps.201400316 
Bertelsen, M., Jeppesen, P., Petersen, L., Thorup, A., Øhlenschlaeger, J., le Quach, P., Christensen, T.Ø., 
Krarup, G., Jørgensen, P., Nordentoft, M., 2008. Five-year follow-up of a randomized multicenter 
trial of intensive early intervention vs standard treatment for patients with a first episode of 
psychotic illness: the OPUS trial. Arch. Gen. Psychiatry 65, 762–771. 
doi:10.1001/archpsyc.65.7.762 
Bertelsen, M., Jeppesen, P., Petersen, L., Thorup, A., OHLENSCHLAeGER, J., Quach, P.L., Christensen, 
T.O., Krarup, G., Jorgensen, P., Nordentoft, M., 2007. Suicidal behaviour and mortality in first-
episode psychosis: the OPUS trial. The British Journal of Psychiatry 191, s140–s146. 
doi:10.1192/bjp.191.51.s140 
19 
 
Best, M.W., Grossman, M., Oyewumi, L.K., Bowie, C.R., 2014. Examination of the Positive and 
Negative Syndrome Scale factor structure and longitudinal relationships with functioning in early 
psychosis: PANSS factor structure and functioning. Early Intervention in Psychiatry n/a-n/a. 
doi:10.1111/eip.12190 
Cacciotti-Saija, C., Langdon, R., Ward, P.B., Hickie, I.B., Guastella, A.J., 2016. Clinical symptoms 
predict concurrent social and global functioning in an early psychosis sample: Clinical symptoms 
predict functioning in early psychosis. Early Intervention in Psychiatry n/a-n/a. 
doi:10.1111/eip.12295 
Carbon, M., Correll, C.U., 2014. Thinking and acting beyond the positive: the role of the cognitive and 
negative symptoms in schizophrenia. CNS Spectrums 19, 35–53. 
doi:10.1017/S1092852914000601 
Carr, J.A.R., Norman, R.G.M., Manchanda, R., 2009. Sociodemographic and clinical characteristics of 
patients presenting with first-episode psychosis and concurrent substance misuse. Early 
Intervention in Psychiatry 3, 75–79. doi:10.1111/j.1751-7893.2008.00100.x 
Cesková, E., Radovan, P., Tomás, K., Hana, K., 2007. One-year follow-up of patients with first-episode 
schizophrenia (comparison between remitters and non-remitters). Neuropsychiatr Dis Treat 3, 
153–160. 
Chang, W.C., Chen, E.S.M., Hui, C.L.M., Chan, S.K.W., Lee, E.H.M., Chen, E.Y.H., 2014. The 
relationships of suicidal ideation with symptoms, neurocognitive function, and psychological 
factors in patients with first-episode psychosis. Schizophrenia Research 157, 12–18. 
doi:10.1016/j.schres.2014.06.009 
Chang, W.C., Hui, C.L.M., Tang, J.Y.M., Wong, G.H.Y., Lam, M.M.L., Chan, S.K.W., Chen, E.Y.H., 
2011. Persistent negative symptoms in first-episode schizophrenia: a prospective three-year 
follow-up study. Schizophr. Res. 133, 22–28. doi:10.1016/j.schres.2011.09.006 
Chang, W.C., Lau, C.F.C., Chan, S.S.I., Hui, C.L.M., Chan, S.K.W., Lee, E.H.M., Lin, J., Chen, E.Y.H., 
2016. Premorbid, clinical and cognitive correlates of primary negative symptoms in first-episode 
psychosis. Psychiatry Research 242, 144–149. doi:10.1016/j.psychres.2016.05.045 
Chang, W.C., Tang, J.Y., Hui, C.L., Lam, M.M., Chan, S.K., Wong, G.H., Chiu, C.P., Chen, E.Y., 2012a. 
Prediction of remission and recovery in young people presenting with first-episode psychosis in 
Hong Kong: A 3-year follow-up study. Australian and New Zealand Journal of Psychiatry 46, 
100–108. doi:10.1177/0004867411428015 
Chang, W.C., Tang, J.Y.M., Hui, C.L.M., Lam, M.M.L., Wong, G.H.Y., Chan, S.K.W., Chiu, C.P.Y., 
Chung, D.W.S., Law, C.W., Tso, S., Chan, K., Hung, S.F., Chen, E.Y.H., 2012b. Duration of 
untreated psychosis: Relationship with baseline characteristics and three-year outcome in first-
episode psychosis. Psychiatry Research 198, 360–365. doi:10.1016/j.psychres.2011.09.006 
Chue, P., Lalonde, J., 2014. Addressing the unmet needs of patients with persistent negative symptoms of 
schizophrenia: emerging pharmacological treatment options. Neuropsychiatric Disease and 
Treatment 777. doi:10.2147/NDT.S43404 
Compton, M.T., Whicker, N.E., Hochman, K.M., 2007. Alcohol and cannabis use in Urban, African 
American, first-episode schizophrenia-spectrum patients: associations with positive and negative 
symptoms. J Clin Psychiatry 68, 1939–1945. 
Corcoran, C.M., Kimhy, D., Parrilla-Escobar, M.A., Cressman, V.L., Stanford, A.D., Thompson, J., 
David, S.B., Crumbley, A., Schobel, S., Moore, H., Malaspina, D., 2011. The relationship of 
social function to depressive and negative symptoms in individuals at clinical high risk for 
psychosis. Psychological Medicine 41, 251–261. doi:10.1017/S0033291710000802 
Dean, K., Walsh, E., Morgan, C., Demjaha, A., Dazzan, P., Morgan, K., Lloyd, T., Fearon, P., Jones, 
P.B., Murray, R.M., 2007. Aggressive behaviour at first contact with services: findings from the 
AESOP First Episode Psychosis Study. Psychological Medicine 37, 547–557. 
doi:10.1017/S0033291706008920 
Díaz, I., Pelayo-Terán, J.M., Pérez-Iglesias, R., Mata, I., Tabarés-Seisdedos, R., Suárez-Pinilla, P., 
Vázquez-Barquero, J.L., Crespo-Facorro, B., 2013. Predictors of clinical remission following a 
20 
 
first episode of non-affective psychosis: Sociodemographics, premorbid and clinical variables. 
Psychiatry Research 206, 181–187. doi:10.1016/j.psychres.2012.10.011 
Díaz-Caneja, C.M., Pina-Camacho, L., Rodríguez-Quiroga, A., Fraguas, D., Parellada, M., Arango, C., 
2015. Predictors of outcome in early-onset psychosis: a systematic review. npj Schizophrenia 1, 
14005. doi:10.1038/npjschz.2014.5 
Dominguez, M.-G., Saka, M.C., Lieb, R., Wittchen, H.-U., van Os, J., 2010. Early Expression of 
Negative/Disorganized Symptoms Predicting Psychotic Experiences and Subsequent Clinical 
Psychosis: A 10-Year Study. American Journal of Psychiatry 167, 1075–1082. 
doi:10.1176/appi.ajp.2010.09060883 
Drake, R.E., Wallach, M.A., 1989. Substance abuse among the chronic mentally ill. Hosp Community 
Psychiatry 40, 1041–1046. 
Drake, R.J., Addington, J., Viswanathan, A.C., Lewis, S.W., Cotter, J., Yung, A.R., Abel, K.M., 2016. 
How Age and Gender Predict Illness Course in a First-Episode Nonaffective Psychosis Cohort. 
The Journal of Clinical Psychiatry e283–e289. doi:10.4088/JCP.14m09369 
Edwards, J., McGorry, P.D., Waddell, F.M., Harrigan, S.M., 1999. Enduring negative symptoms in first-
episode psychosis: comparison of six methods using follow-up data. Schizophrenia Research 40, 
147–158. doi:10.1016/S0920-9964(99)00043-2 
Endicott, J., Spitzer, R.L., Fleiss, J.L., Cohen, J., 1976. The global assessment scale. A procedure for 
measuring overall severity of psychiatric disturbance. Arch. Gen. Psychiatry 33, 766–771. 
Esterberg, M., Compton, M., 2012. Family history of psychosis negatively impacts age at onset, negative 
symptoms, and duration of untreated illness and psychosis in first-episode psychosis patients. 
Psychiatry Research 197, 23–28. doi:10.1016/j.psychres.2012.03.001 
Field, A.P., 2009. Discovering statistics using SPSS: (and sex, drugs and rock “n” roll), 3rd ed. ed. SAGE 
Publications, Los Angeles. 
Fisher, H., Theodore, K., Power, P., Chisholm, B., Fuller, J., Marlowe, K., Aitchison, K.J., Tanna, R., 
Joyce, J., Sacks, M., Craig, T., Johnson, S., 2008. Routine evaluation in first episode psychosis 
services: feasibility and results from the MiData project. Social Psychiatry and Psychiatric 
Epidemiology 43, 960–967. doi:10.1007/s00127-008-0386-1 
Foley, S.R., Browne, S., Clarke, M., Kinsella, A., Larkin, C., O’Callaghan, E., 2007. Is violence at 
presentation by patients with first-episode psychosis associated with duration of untreated 
psychosis? Soc Psychiatry Psychiatr Epidemiol 42, 606–610. doi:10.1007/s00127-007-0217-9 
Fraguas, D., del Rey-Mejías, Á., Moreno, C., Castro-Fornieles, J., Graell, M., Otero, S., Gonzalez-Pinto, 
A., Moreno, D., Baeza, I., Martínez-Cengotitabengoa, M., Arango, C., Parellada, M., 2014. 
Duration of untreated psychosis predicts functional and clinical outcome in children and 
adolescents with first-episode psychosis: A 2-year longitudinal study. Schizophrenia Research 
152, 130–138. doi:10.1016/j.schres.2013.11.018 
Fusar-Poli, P., Borgwardt, S., Bechdolf, A., Addington, J., Riecher-Rössler, A., Schultze-Lutter, F., 
Keshavan, M., Wood, S., Ruhrmann, S., Seidman, L.J., Valmaggia, L., Cannon, T., Velthorst, E., 
De Haan, L., Cornblatt, B., Bonoldi, I., Birchwood, M., McGlashan, T., Carpenter, W., McGorry, 
P., Klosterkötter, J., McGuire, P., Yung, A., 2013. The Psychosis High-Risk State: A 
Comprehensive State-of-the-Art Review. JAMA Psychiatry 70, 107. 
doi:10.1001/jamapsychiatry.2013.269 
Fusar-Poli, P., Papanastasiou, E., Stahl, D., Rocchetti, M., Carpenter, W., Shergill, S., McGuire, P., 2015. 
Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-
Controlled Trials. Schizophrenia Bulletin 41, 892–899. doi:10.1093/schbul/sbu170 
Gaebel, W., Riesbeck, M., Wölwer, W., Klimke, A., Eickhoff, M., von Wilmsdorff, M., Heuser, I., Maier, 
W., Klosterkötter, J., Falkai, P., Schlösser, R., Schmitt, A., Riedel, M., Klingberg, S., Köpcke, 
W., Ohmann, C., Möller, H.-J., 2014. Rates and predictors of remission in first-episode 
schizophrenia within 1year of antipsychotic maintenance treatment. Results of a randomized 
controlled trial within the German Research Network on Schizophrenia. Schizophrenia Research 
152, 478–486. doi:10.1016/j.schres.2013.04.012 
21 
 
Galderisi, S., Mucci, A., Bitter, I., Libiger, J., Bucci, P., Wolfgang Fleischhacker, W., Kahn, R.S., for the 
EUFEST Study Group, 2013. Persistent negative symptoms in first episode patients with 
schizophrenia: Results from the European First Episode Schizophrenia Trial. European 
Neuropsychopharmacology 23, 196–204. doi:10.1016/j.euroneuro.2012.04.019 
Gee, B., Hodgekins, J., Fowler, D., Marshall, M., Everard, L., Lester, H., Jones, P.B., Amos, T., P. Singh, 
S., Sharma, V., Freemantle, N., Birchwood, M., 2016. The course of negative symptom in first 
episode psychosis and the relationship with social recovery. Schizophrenia Research 174, 165–
171. doi:10.1016/j.schres.2016.04.017 
Gregg, L., Barrowclough, C., Haddock, G., 2007. Reasons for increased substance use in psychosis. 
Clinical Psychology Review 27, 494–510. doi:10.1016/j.cpr.2006.09.004 
Hadden, K.L., LeDrew, K., Hogan, K., Thomas, B., 2016. Impact of comorbid cannabis use on outcome 
in first episode psychosis: Cannabis use in first-episode psychosis. Early Intervention in 
Psychiatry. doi:10.1111/eip.12377 
Hafner, H., Maurer, K., Loffler, W., Riecher-Rossler, A., 1993. The influence of age and sex on the onset 
and early course of schizophrenia. The British Journal of Psychiatry 162, 80–86. 
doi:10.1192/bjp.162.1.80 
Harvey, P.D., Koren, D., Reichenberg, A., Bowie, C.R., 2006. Negative Symptoms and Cognitive 
Deficits: What Is the Nature of Their Relationship? Schizophrenia Bulletin 32, 250–258. 
doi:10.1093/schbul/sbj011 
Hunter, R., Barry, S., 2012. Negative symptoms and psychosocial functioning in schizophrenia: 
Neglected but important targets for treatment. European Psychiatry 27, 432–436. 
doi:10.1016/j.eurpsy.2011.02.015 
Jauhar, S., McKenna, P.J., Radua, J., Fung, E., Salvador, R., Laws, K.R., 2014. Cognitive-behavioural 
therapy for the symptoms of schizophrenia: systematic review and meta-analysis with 
examination of potential bias. The British Journal of Psychiatry 204, 20–29. 
doi:10.1192/bjp.bp.112.116285 
Jeppesen, P., Petersen, L., Thorup, A., Abel, M.-B., Øhlenschlaeger, J., Christensen, T.Ø., Krarup, G., 
Jørgensen, P., Nordentoft, M., 2008. The association between pre-morbid adjustment, duration of 
untreated psychosis and outcome in first-episode psychosis. Psychol Med 38, 1157–1166. 
doi:10.1017/S0033291708003449 
Kane, J.M., Leucht, S., Carpenter, D., Docherty, J.P., Expert Consensus Panel for Optimizing 
Pharmacologic Treatment of Psychotic Disorders, 2003. The expert consensus guideline series. 
Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, 
and summary. J Clin Psychiatry 64 Suppl 12, 5–19. 
Kay, S.R., Fiszbein, A., Opler, L.A., 1987. The positive and negative syndrome scale (PANSS) for 
schizophrenia. Schizophr Bull 13, 261–276. 
Kay, S.R., Sevy, S., 1990. Pyramidical Model of Schizophrenia. Schizophrenia Bulletin 16, 537–545. 
doi:10.1093/schbul/16.3.537 
Khantzian, E.J., 1997. The Self-Medication Hypothesis of Substance Use Disorders: A Reconsideration 
and Recent Applications. Harvard Review of Psychiatry 4, 231–244. 
doi:10.3109/10673229709030550 
Kim, K.R., Song, Y.Y., Park, J.Y., Lee, E.H., Lee, M., Lee, S.Y., Kang, J.I., Lee, E., Yoo, S.W., An, 
S.K., Kwon, J.S., 2013. The relationship between psychosocial functioning and resilience and 
negative symptoms in individuals at ultra-high risk for psychosis. Australian & New Zealand 
Journal of Psychiatry 47, 762–771. doi:10.1177/0004867413488218 
Kirkpatrick, B., 2014. Progress in the Study of Negative Symptoms. Schizophrenia Bulletin 40, S101–
S106. doi:10.1093/schbul/sbt158 
Kjelby, E., Jørgensen, H.A., Kroken, R.A., Løberg, E.-M., Johnsen, E., 2011. Anti-depressive 
effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized 
trial. BMC Psychiatry 11. doi:10.1186/1471-244X-11-145 
22 
 
Köhler, S., van der Werf, M., Hart, B., Morrison, G., McCreadie, R., Kirkpatrick, B., Verkaaik, M., 
Krabbendam, L., Verhey, F., van Os, J., Allardyce, J., 2009. Evidence that better outcome of 
psychosis in women is reversed with increasing age of onset: A population-based 5-year follow-
up study. Schizophrenia Research 113, 226–232. doi:10.1016/j.schres.2009.05.017 
Køster, A., Lajer, M., Lindhardt, A., Rosenbaum, B., 2008. Gender differences in first episode psychosis. 
Social Psychiatry and Psychiatric Epidemiology 43, 940–946. doi:10.1007/s00127-008-0384-3 
Lang, F.U., Kösters, M., Lang, S., Becker, T., Jäger, M., 2013. Psychopathological long-term outcome of 
schizophrenia - a review. Acta Psychiatrica Scandinavica 127, 173–182. doi:10.1111/acps.12030 
Langeveld, J., Bjørkly, S., Auestad, B., Barder, H., Evensen, J., ten Velden Hegelstad, W., Joa, I., 
Johannessen, J.O., Larsen, T.K., Melle, I., Opjordsmoen, S., Røssberg, J.I., Rund, B.R., 
Simonsen, E., Vaglum, P., McGlashan, T., Friis, S., 2014. Treatment and violent behavior in 
persons with first episode psychosis during a 10-year prospective follow-up study. Schizophrenia 
Research 156, 272–276. doi:10.1016/j.schres.2014.04.010 
Large, M.M., Nielssen, O., 2011. Violence in first-episode psychosis: A systematic review and meta-
analysis. Schizophrenia Research 125, 209–220. doi:10.1016/j.schres.2010.11.026 
Levine, S.Z., Leucht, S., 2013. Attaining and sustaining remission of predominant negative symptoms. 
Schizophr. Res. 143, 60–64. doi:10.1016/j.schres.2012.11.010 
Little, R.J.A., Rubin, D.B., 1991. Statistical Analysis with Missing Data. Journal of Educational Statistics 
16, 150. doi:10.2307/1165119 
Lyne, J., O’Donoghue, B., Owens, E., Renwick, L., Madigan, K., Kinsella, A., Clarke, M., Turner, N., 
O’Callaghan, E., 2012. Prevalence of item level negative symptoms in first episode psychosis 
diagnoses. Schizophr. Res. 135, 128–133. doi:10.1016/j.schres.2012.01.004 
Malla, A., 2005. First-Episode Psychosis: Psychopathology, Quality of Life, and Functional Outcome. 
Schizophrenia Bulletin 31, 650–671. doi:10.1093/schbul/sbi031 
Malla, A.K., Norman, R.M.G., Takhar, J., Manchanda, R., Townsend, L., Scholten, D., Haricharan, R., 
2004. Can Patients at Risk for Persistent Negative Symptoms Be Identified During Their First 
Episode of Psychosis?: The Journal of Nervous and Mental Disease 192, 455–463. 
doi:10.1097/01.nmd.0000131804.34977.c1 
Mané, A., Fernández-Expósito, M., Bergé, D., Gómez-Pérez, L., Sabaté, A., Toll, A., Diaz, L., Diez-Aja, 
C., Perez, V., 2015. Relationship between cannabis and psychosis: Reasons for use and associated 
clinical variables. Psychiatry Research 229, 70–74. doi:10.1016/j.psychres.2015.07.070 
Marchesi, C., Affaticati, A., Monici, A., De Panfilis, C., Ossola, P., Tonna, M., 2015. Severity of core 
symptoms in first episode schizophrenia and long-term remission. Psychiatry Research 225, 129–
132. doi:10.1016/j.psychres.2014.11.005 
Marchesi, C., Affaticati, A., Monici, A., De Panfilis, C., Ossola, P., Tonna, M., 2014a. Predictors of 
symptomatic remission in patients with first-episode schizophrenia: A 16years follow-up study. 
Comprehensive Psychiatry 55, 778–784. doi:10.1016/j.comppsych.2013.12.011 
Marchesi, C., Affaticati, A., Monici, A., De Panfilis, C., Ossola, P., Tonna, M., 2014b. Predictors of 
symptomatic remission in patients with first-episode schizophrenia: a 16years follow-up study. 
Compr Psychiatry 55, 778–784. doi:10.1016/j.comppsych.2013.12.011 
Meyer, E.C., Carrion, R.E., Cornblatt, B.A., Addington, J., Cadenhead, K.S., Cannon, T.D., McGlashan, 
T.H., Perkins, D.O., Tsuang, M.T., Walker, E.F., Woods, S.W., Heinssen, R., Seidman, L.J., the 
NAPLS group, 2014. The Relationship of Neurocognition and Negative Symptoms to Social and 
Role Functioning Over Time in Individuals at Clinical High Risk in the First Phase of the North 
American Prodrome Longitudinal Study. Schizophrenia Bulletin 40, 1452–1461. 
doi:10.1093/schbul/sbt235 
Milev, P., Ho, B.-C., Arndt, S., Andreasen, N.C., 2005. Predictive Values of Neurocognition and 
Negative Symptoms on Functional Outcome in Schizophrenia: A Longitudinal First-Episode 
Study With 7-Year Follow-Up. American Journal of Psychiatry 162, 495–506. 
doi:10.1176/appi.ajp.162.3.495 
23 
 
Millan, M.J., Fone, K., Steckler, T., Horan, W.P., 2014. Negative symptoms of schizophrenia: Clinical 
characteristics, pathophysiological substrates, experimental models and prospects for improved 
treatment. European Neuropsychopharmacology 24, 645–692. 
doi:10.1016/j.euroneuro.2014.03.008 
Mitter, N., Subramaniam, M., Abdin, E., Poon, L.Y., Verma, S., 2013. Predictors of suicide in Asian 
patients with first episode psychosis. Schizophrenia Research 151, 274–278. 
doi:10.1016/j.schres.2013.10.006 
Morgan, V., Korten, A., Jablensky, A., 2006. Modifiable risk factors for hospitalization among people 
with psychosis: evidence from the National Study of Low Prevalence (Psychotic) Disorders. 
Australian and New Zealand Journal of Psychiatry 40, 683–690. doi:10.1080/j.1440-
1614.2006.01868.x 
Norman, R.M.G., Malla, A.K., Manchanda, R., Harricharan, R., Takhar, J., Northcott, S., 2005. Social 
support and three-year symptom and admission outcomes for first episode psychosis. 
Schizophrenia Research 80, 227–234. doi:10.1016/j.schres.2005.05.006 
Norman, R.M.G., Windell, D., Manchanda, R., Harricharan, R., Northcott, S., 2012. Social support and 
functional outcomes in an early intervention program. Schizophrenia Research 140, 37–40. 
doi:10.1016/j.schres.2012.07.003 
Novick, D., Haro, J.M., Suarez, D., Vieta, E., Naber, D., 2009. Recovery in the outpatient setting: 36-
month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr. 
Res. 108, 223–230. doi:10.1016/j.schres.2008.11.007 
Ochoa, S., Usall, J., Cobo, J., Labad, X., Kulkarni, J., 2012. Gender Differences in Schizophrenia and 
First-Episode Psychosis: A Comprehensive Literature Review. Schizophrenia Research and 
Treatment 2012, 1–9. doi:10.1155/2012/916198 
Østergaard Christensen, T., Vesterager, L., Krarup, G., Olsen, B.B., Melau, M., Gluud, C., Nordentoft, 
M., 2014. Cognitive remediation combined with an early intervention service in first episode 
psychosis. Acta Psychiatr Scand 130, 300–310. doi:10.1111/acps.12287 
Patel, R., Jayatilleke, N., Broadbent, M., Chang, C.-K., Foskett, N., Gorrell, G., Hayes, R.D., Jackson, R., 
Johnston, C., Shetty, H., Roberts, A., McGuire, P., Stewart, R., 2015. Negative symptoms in 
schizophrenia: a study in a large clinical sample of patients using a novel automated method. 
BMJ Open 5, e007619. doi:10.1136/bmjopen-2015-007619 
Petersen, L., Thorup, A., Øqhlenschlaeger, J., Christensen, T.Ø., Jeppesen, P., Krarup, G., Jørrgensen, P., 
Mortensen, E.L., Nordentoft, M., 2008. Predictors of remission and recovery in a first-episode 
schizophrenia spectrum disorder sample: 2-year follow-up of the OPUS trial. Can J Psychiatry 
53, 660–670. 
Pitt, L., Kilbride, M., Nothard, S., Welford, M., Morrison, A.P., 2007. Researching recovery from 
psychosis: a user-led project. Psychiatric Bulletin 31, 55–60. doi:10.1192/pb.bp.105.008532 
Pompili, M., Serafini, G., Innamorati, M., Lester, D., Shrivastava, A., Girardi, P., Nordentoft, M., 2011. 
Suicide risk in first episode psychosis: A selective review of the current literature. Schizophrenia 
Research 129, 1–11. doi:10.1016/j.schres.2011.03.008 
Potvin, S., Sepehry, A.A., Stip, E., 2005. A meta-analysis of negative symptoms in dual diagnosis 
schizophrenia. Psychological Medicine 36, 431. doi:10.1017/S003329170500574X 
Rabinowitz, J., Levine, S.Z., Garibaldi, G., Bugarski-Kirola, D., Berardo, C.G., Kapur, S., 2012. Negative 
symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis 
of CATIE data. Schizophrenia Research 137, 147–150. doi:10.1016/j.schres.2012.01.015 
Rietschel, L., Lambert, M., Karow, A., Zink, M., Müller, H., Heinz, A., de Millas, W., Janssen, B., 
Gaebel, W., Schneider, F., Naber, D., Juckel, G., Krüger-Özgürdal, S., Wobrock, T., Wagner, M., 
Maier, W., Klosterkötter, J., Bechdolf, A., PREVENT study group, 2015. Clinical high risk for 
psychosis: gender differences in symptoms and social functioning: Gender differences in HR for 
psychosis. Early Intervention in Psychiatry n/a-n/a. doi:10.1111/eip.12240 
24 
 
Robertson, B.R., Prestia, D., Twamley, E.W., Patterson, T.L., Bowie, C.R., Harvey, P.D., 2014. Social 
competence versus negative symptoms as predictors of real world social functioning in 
schizophrenia. Schizophrenia Research 160, 136–141. doi:10.1016/j.schres.2014.10.037 
Schafer, J.L., Graham, J.W., 2002. Missing data: our view of the state of the art. Psychol Methods 7, 147–
177. 
Schennach-Wolff, R., Jäger, M., Mayr, A., Meyer, S., Kühn, K.-U., Klingberg, S., Heuser, I., 
Klosterkötter, J., Gastpar, M., Schmitt, A., Schlösser, R., Schneider, F., Gaebel, W., Seemüller, 
F., Möller, H.-J., Riedel, M., 2011. Predictors of response and remission in the acute treatment of 
first-episode schizophrenia patients — Is it all about early response? European 
Neuropsychopharmacology 21, 370–378. doi:10.1016/j.euroneuro.2010.10.003 
Schubert, K.O., Clark, S.R., Baune, B.T., 2015. The use of clinical and biological characteristics to 
predict outcome following First Episode Psychosis. Australian & New Zealand Journal of 
Psychiatry 49, 24–35. doi:10.1177/0004867414560650 
Schultz, S.K., Miller, D.D., Oliver, S.E., Arndt, S., Flaum, M., Andreasen, N.C., 1997. The life course of 
schizophrenia: age and symptom dimensions. Schizophr. Res. 23, 15–23. doi:10.1016/S0920-
9964(96)00087-4 
Seddon, J.L., Birchwood, M., Copello, A., Everard, L., Jones, P.B., Fowler, D., Amos, T., Freemantle, N., 
Sharma, V., Marshall, M., Singh, S.P., 2016. Cannabis Use Is Associated With Increased 
Psychotic Symptoms and Poorer Psychosocial Functioning in First-Episode Psychosis: A Report 
From the UK National EDEN Study. Schizophrenia Bulletin 42, 619–625. 
doi:10.1093/schbul/sbv154 
Sevy, S., Robinson, D.G., Holloway, S., Alvir, J.M., Woerner, M.G., Bilder, R., Goldman, R., Lieberman, 
J., Kane, J., 2008. Correlates of substance misuse in patients with first-episode schizophrenia and 
schizoaffective disorder: Substance misuse in schizophrenia. Acta Psychiatrica Scandinavica 104, 
367–374. doi:10.1111/j.1600-0447.2001.00452.x 
Simon, N., Belzeaux, R., Adida, M., Azorin, J.-M., 2015. Symptômes négatifs dans la schizophrénie et 
addiction. L’Encéphale 41, 6S27-6S31. doi:10.1016/S0013-7006(16)30007-0 
Singh, S.P., 2010. Early intervention in psychosis. Br J Psychiatry 196, 343–345. 
doi:10.1192/bjp.bp.109.075804 
Singh, S.P., 2000. Three-year outcome of first-episode psychoses in an established community psychiatric 
service. The British Journal of Psychiatry 176, 210–216. doi:10.1192/bjp.176.3.210 
Singh, S.P., Cooper, J.E., Fisher, H.L., Tarrant, C.J., Lloyd, T., Banjo, J., Corfe, S., Jones, P., 2005. 
Determining the chronology and components of psychosis onset: The Nottingham Onset 
Schedule (NOS). Schizophrenia Research 80, 117–130. doi:10.1016/j.schres.2005.04.018 
Sipos, A., 2001. Patterns and predictors of hospitalisation in first-episode psychosis: Prospective cohort 
study. The British Journal of Psychiatry 178, 518–523. doi:10.1192/bjp.178.6.518 
Stone, J.M., Fisher, H.L., Major, B., Chisholm, B., Woolley, J., Lawrence, J., Rahaman, N., Joyce, J., 
Hinton, M., Johnson, S., Young, A.H., 2014. Cannabis use and first-episode psychosis: 
relationship with manic and psychotic symptoms, and with age at presentation. Psychological 
Medicine 44, 499–506. doi:10.1017/S0033291713000883 
Tait, L., Birchwood, M., Trower, P., 2002. A new scale (SES) to measure engagement with community 
mental health services. Journal of Mental Health 11, 191–198. doi:10.1080/09638230020023570-
2 
Tandberg, M., Ueland, T., Andreassen, O.A., Sundet, K., Melle, I., 2012. Factors associated with 
occupational and academic status in patients with first-episode psychosis with a particular focus 
on neurocognition. Soc Psychiatry Psychiatr Epidemiol 47, 1763–1773. doi:10.1007/s00127-012-
0477-x 
Tang, J.Y.-M., Chang, W.-C., Hui, C.L.-M., Wong, G.H.-Y., Chan, S.K.-W., Lee, E.H.-M., Yeung, W.-
S., Wong, C.-K., Tang, W.-N., Chan, W.-F., Pang, E.P.-F., Tso, S., Ng, R.M.-K., Hung, S.-F., 
Dunn, E.L.-W., Sham, P.-C., Chen, E.Y.-H., 2014. Prospective relationship between duration of 
25 
 
untreated psychosis and 13-year clinical outcome: A first-episode psychosis study. Schizophrenia 
Research 153, 1–8. doi:10.1016/j.schres.2014.01.022 
Tarricone, I., Boydell, J., Panigada, S., Allegri, F., Marcacci, T., Minenna, M.G., Kokona, A., Triolo, F., 
Storbini, V., Michetti, R., Morgan, C., Di Forti, M., Murray, R.M., Berardi, D., 2014. The impact 
of substance use at psychosis onset on First Episode Psychosis course: Results from a 1 year 
follow-up study in Bologna. Schizophrenia Research 153, 60–63. 
doi:10.1016/j.schres.2014.01.014 
Thompson, J., Berk, M., Dean, O., Kohlmann, K., Jeavons, S., Bush, A., Copolov, D., 2011. Who’s left? 
Symptoms of schizophrenia that predict clinical trial dropout. Hum Psychopharmacol 26, 609–
613. doi:10.1002/hup.1253 
Thorup, A., Albert, N., Bertelsen, M., Petersen, L., Jeppesen, P., Le Quack, P., Krarup, G., Jørgensen, P., 
Nordentoft, M., 2014. Gender differences in first-episode psychosis at 5-year follow-up – two 
different courses of disease? Results from the OPUS study at 5-year follow-up. European 
Psychiatry 29, 44–51. doi:10.1016/j.eurpsy.2012.11.005 
Thorup, A., Petersen, L., Jeppesen, P., Ohlenschlaeger, J., Christensen, T., Krarup, G., Jorgensen, P., 
Nordentoft, M., 2007. Gender differences in young adults with first-episode schizophrenia 
spectrum disorders at baseline in the Danish OPUS study. J. Nerv. Ment. Dis. 195, 396–405. 
doi:10.1097/01.nmd.0000253784.59708.dd 
Tseliou, F., Johnson, S., Major, B., Rahaman, N., Joyce, J., Lawrence, J., Mann, F., Tapfumaneyi, A., 
Chisholm, B., Chamberlain-Kent, N., Hinton, M.F., Fisher, H.L., MiData Consortium, 2015. 
Gender differences in one-year outcomes of first-presentation psychosis patients in inner-city UK 
Early Intervention Services: 1-year outcomes of EI services by gender. Early Intervention in 
Psychiatry n/a-n/a. doi:10.1111/eip.12235 
Üçok, A., Ergül, C., 2014. Persistent negative symptoms after first episode schizophrenia: A 2-year 
follow-up study. Schizophr. Res. 158, 241–246. doi:10.1016/j.schres.2014.07.021 
Uçok, A., Polat, A., Cakir, S., Genç, A., 2006. One year outcome in first episode schizophrenia. 
Predictors of relapse. Eur Arch Psychiatry Clin Neurosci 256, 37–43. doi:10.1007/s00406-005-
0598-2 
Üçok, A., Serbest, S., Kandemir, P.E., 2011. Remission after first-episode schizophrenia: Results of a 
long-term follow-up. Psychiatry Research 189, 33–37. doi:10.1016/j.psychres.2010.11.013 
van der Ven, E., Bourque, F., Joober, R., Selten, J.-P., Malla, A.K., 2012. Comparing the clinical 
presentation of first-episode psychosis across different migrant and ethnic minority groups in 
Montreal, Quebec. Can J Psychiatry 57, 300–308. 
Veling, W., 2013. Ethnic minority position and risk for psychotic disorders. Curr Opin Psychiatry 26, 
166–171. doi:10.1097/YCO.0b013e32835d9e43 
Ventriglio, A., Gentile, A., Bonfitto, I., Stella, E., Mari, M., Steardo, L., Bellomo, A., 2016. Suicide in the 
Early Stage of Schizophrenia. Frontiers in Psychiatry 7. doi:10.3389/fpsyt.2016.00116 
Ventura, J., Subotnik, K.L., Gitlin, M.J., Gretchen-Doorly, D., Ered, A., Villa, K.F., Hellemann, G.S., 
Nuechterlein, K.H., 2015. Negative symptoms and functioning during the first year after a recent 
onset of schizophrenia and 8years later. Schizophrenia Research 161, 407–413. 
doi:10.1016/j.schres.2014.10.043 
Verdoux, H., Liraud, F., Gonzales, B., Assens, F., Abalan, F., van Os, J., 2001. Predictors and outcome 
characteristics associated with suicidal behaviour in early psychosis: a two-year follow-up of 
first-admitted subjects. Acta Psychiatrica Scandinavica 103, 347–354. doi:10.1034/j.1600-
0447.2001.00202.x 
Verma, S., Subramaniam, M., Abdin, E., Poon, L.Y., Chong, S.A., 2012. Symptomatic and functional 
remission in patients with first-episode psychosis: Remission in first-episode psychosis. Acta 
Psychiatrica Scandinavica 126, 282–289. doi:10.1111/j.1600-0447.2012.01883.x 
White, I.R., Royston, P., Wood, A.M., 2011. Multiple imputation using chained equations: Issues and 
guidance for practice. Statistics in Medicine 30, 377–399. doi:10.1002/sim.4067 
26 
 
Willhite, R.K., Niendam, T.A., Bearden, C.E., Zinberg, J., O’Brien, M.P., Cannon, T.D., 2008. Gender 
differences in symptoms, functioning and social support in patients at ultra-high risk for 
developing a psychotic disorder. Schizophrenia Research 104, 237–245. 
doi:10.1016/j.schres.2008.05.019 
Winsper, C., Singh, S.P., Marwaha, S., Amos, T., Lester, H., Everard, L., Jones, P., Fowler, D., Marshall, 
M., Lewis, S., Sharma, V., Freemantle, N., Birchwood, M., 2013. Pathways to Violent Behavior 
During First-Episode Psychosis: A Report From the UK National EDEN Study. JAMA 
Psychiatry 70, 1287. doi:10.1001/jamapsychiatry.2013.2445 
World Health Organization (Ed.), 1993. The ICD-10 classification of mental and behavioural disorders: 
diagnostic criteria for research. World Health Organization, Geneva. 
 
